Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy
Table 5
Adverse event data.
A5 run-in
A10 run-in
A10
A5
T40/A5
T80/A5
A10
T40/A10
T80/A10
Number of patients treated
Patients with investigator defined drug-related AEs (%)
77 (27.9)
43 (6.2)
32 (5.9)
27 (6.2)
27 (8.6)
25 (7.9)
31 (9.8)
Patients with AEs leading to discontinuation (%)
21 (7.6)
9 (1.3)
6 (1.1)
5 (1.1)
7 (2.2)
9 (2.9)
4 (1.3)
Patients with SAEs (%)
1 (0.4)
4 (0.6)
3 (0.5)
1 (0.2)
1 (0.3)
3 (1.0)
0 (0.0)
Note that AE data are reported for all patients treated. This is slightly higher than the number of patients with BP measurements available and reported in the efficacy analysis.
